PT - JOURNAL ARTICLE AU - Sara Gandini AU - Maurizio Rainisio AU - Maria Luisa Iannuzzo AU - Federica Bellerba AU - Francesco Cecconi AU - Luca Scorrano TI - No evidence of association between schools and SARS-CoV-2 second wave in Italy AID - 10.1101/2020.12.16.20248134 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.16.20248134 4099 - http://medrxiv.org/content/early/2020/12/18/2020.12.16.20248134.short 4100 - http://medrxiv.org/content/early/2020/12/18/2020.12.16.20248134.full AB - During Covid-19 pandemic, school closure has been mandated in analogy to its known effect against influenza, but it is unclear whether schools are early amplifiers of Covid19 cases. By analyzing the case scenario of school reopening across the twenty-one Italian regions, we did not find evidence that schools drove the second SARS-CoV-2 wave. Indeed, from September 12 to November 7 2020, SARS-CoV-2 incidence among students was lower than that in the general population of all but two Italian regions. From August 28 to October 25 in Veneto where school reopened on September 14, the growth of SARS-CoV-2 incidence measured across all age groups was lower in school age individuals, maximal in 20-29 and 45-49 years old individuals. Moreover, the increase in Covid19 reproduction number Rt was not associated with the different school opening dates. Reciprocally, school closures in two regions where they were implemented before other measures did not affect the rate of Rt decline. In schools, despite the high frequency of tests per week, secondary infections were <1%, and clusters in a representative November week infrequent. Thus, our prospective analysis does not support a role for school reopening as a driver of the second wave of SARS-CoV-2 epidemics in Italy.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is an observational studyFunding StatementThis work was partially supported by the Italian Ministry of Health with Ricerca Corrente and 5x1000 funds (to SG). Federica Bellerba is a PhD student at the European School of Molecular Medicine (SEMM), Milan, Italy.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data are retrieved from public access databasesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are retrieved from public access databases https://github.com/pcm-dpc/COVID-19